×
Back to Agenda
Session 4 Track 2: Optimizing Oligonucleotide Therapeutics: Translating PK/PD and Tissue Half-Life into Smarter Dose Selection and Risk Assessment
Session Chair(s)
Tod Harper, PhD
Scientific Associate Director, Amgen, United States
Sree Rayavarapu, DVM, PhD
Toxicologist, FDA, United States
Session 4 Track 2: Optimizing Oligonucleotide Therapeutics: Translating PK/PD and Tissue Half-Life into Smarter Dose Selection and Risk Assessment
Speaker(s)
Luc Raymond Albert Rougee, PhD, MS
Director, Eli Lilly & Company, United States
Translational PK/PD Modeling Considerations
Meena Meena, PhD
SVP of Translational DMPK and Clinical Pharmacology, Stoke Therapeutics, United States
Role of Tissue Half Life in Designing Clinical Studies
Tod Harper, PhD
Scientific Associate Director, Amgen, United States
Nonclinical Dose Selection, Safety Margins, and Translational Strategies for Oligonucleotide-based Therapeutics: Results from an IQ DruSafe ONT Working Group Cross-Industry Survey
Have an account?